1. Medtech Insight
  2. >>Archive

Surx Inc.

Dissatisfied with current invasive and complicated surgical techniques for stress urinary incontinence (SUI), the founders of [Surx Inc.] believe they can offer a better approach with a minimally invasive outpatient procedure that uses low power radio frequency (RF) to shrink collagen on the pelvic floor, and return stretched tissues to their normal anatomical position. SUI affects some 6.5 million women in the US, and more than 18 million worldwide

Stress Urinary Incontinence is the involuntary leakage of urine during such mundane normal activities as coughing, sneezing, laughing or walking. It occurs when muscles and tissue in the pelvic floor and urethra stretch and are weakened, preventing natural continence mechanisms from stopping urine loss. Women are much more likely than men to be afflicted, both because of physiological differences and the unique stress that childbearing places on their bodies. Some 10 million women in the US, and more than 18 million worldwide, suffer from the condition.

Stress incontinence carries less of a stigma than it did a generation ago, but it is still an underreported and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

MHRA Opens Second AI Airlock Program For Applications

 
• By Natasha Barrow

"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.

Stealth Mode AI Imaging Startup Faction Imaging Raises $10M

 
• By Natasha Barrow

Faction Imaging has come out of stealth mode following six years of research and development studying medical imaging workflows in India, Japan and the US.

Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation

 
• By Shubham Singh

Remepy is exploring two potential regulatory pathways to support this strategy. The first is a combination product pathway that would formally integrate software and drug into a single therapeutic entity. The second is the FDA’s Prescription Drug Use-Related Software (PDURS) pathway.